The TSX Venture Exchange has accepted for filing the company's prospectus supplement dated Aug. 23, 2019, to Essa's base shelf prospectus dated July 12, 2018, respecting the company's public offering announced on Aug. 23, 2019, and which closed on Aug. 27, 2019, are as follows.
Number of shares: 6,080,596 common shares in the company
Warrants: 11,919,404 prefinanced share purchase warrants (together with the shares, the securities)
Purchase price: $2 (U.S.) per security
Warrant nominal exercise price: Each warrant was prefinanced except for a nominal exercise price of 0.01 cent, with such warrants being exercisable until Aug. 27, 2024.
Insider/pro group participation: The insider participation consisted of an aggregate of 1,704,493 shares purchased by Clarus Lifesciences III LP, of which Clarus Ventures III GP LP is the general partner, and an aggregate of 2.92 million warrants purchased by certain affiliated BVF funds, of which BVF Partners LP is the general partner and BVF Inc. (controlled by Mark Lampert) is the general partner of BVF Partners LP. There was no pro group participation. Further details are set out below.
Insiders: Clarus Lifesciences III LP, 1,704,493 shares;
Biotechnology Value Fund LP, 1,481,634 warrants;
Biotechnology Value Fund II LP, 1,235,030 warrants;
Biotechnology Value Trading Fund OS LP, 203,336 warrants
Agents' fees: The selling group was paid a cash commission equal to 7.0 per cent of the gross proceeds except in respect of securities issued to certain specified purchasers, in which case the cash commission was 3.5 per cent.
© 2019 Canjex Publishing Ltd. All rights reserved.